Mylan Says Celgene Claims Still Timely In Antitrust Suit
Mylan Pharmaceuticals Inc.'s antitrust lawsuit accusing Celgene Corp. of stifling generic competition for the brand-name cancer drug Thalomid isn't barred by the four-year statute of limitations because the clock didn't begin...To view the full article, register now.
Already a subscriber? Click here to view full article